Herrlinger KR - Search Results

1

[Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011].

Dignass A, Preiss JC, Aust DE, Autschbach F, Ballauff A, Barretton G, Bokemeyer B, Fichtner-Feigl S, Hagel S, Herrlinger KR, Jantschek G, Kroesen A, Kruis W, Kucharzik T, Langhorst J, Reinshagen M, Rogler G, Schleiermacher D, Schmidt C, Schreiber S, Schulze H, Stange E, Zeitz M, Hoffmann JC, Stallmach A. Dignass A, et al. Among authors: herrlinger kr. Z Gastroenterol. 2011 Sep;49(9):1276-341. doi: 10.1055/s-0031-1281666. Epub 2011 Aug 24. Z Gastroenterol. 2011. PMID: 21866493 German. No abstract available.

2

[Azathioprine in chronic inflammatory bowel diseases. Evidence base].

Herrlinger K, Stange EF. Herrlinger K, et al. Med Klin (Munich). 2000 Apr 15;95(4):201-6. doi: 10.1007/pl00002107. Med Klin (Munich). 2000. PMID: 10808301 Review. German.

3

The pancreas and inflammatory bowel diseases.

Herrlinger KR, Stange EF. Herrlinger KR, et al. Int J Pancreatol. 2000 Jun;27(3):171-9. doi: 10.1385/IJGC:27:3:171. Int J Pancreatol. 2000. PMID: 10952399 Review.

4

Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use.

Herrlinger KR, Noftz MK, Fellermann K, Schmidt K, Steinhoff J, Stange EF. Herrlinger KR, et al. Aliment Pharmacol Ther. 2001 Mar;15(3):363-9. doi: 10.1046/j.1365-2036.2001.00940.x. Aliment Pharmacol Ther. 2001. PMID: 11207511 Free article.

5

[Sweet syndrome and erythema nodosum in ulcerative colitis, refractory to steroids: successful treatment with tacrolimus].

Fellermann K, Rudolph B, Witthöft T, Herrlinger KR, Tronnier M, Ludwig D, Stange EF. Fellermann K, et al. Among authors: herrlinger kr. Med Klin (Munich). 2001 Feb 15;96(2):105-8. doi: 10.1007/pl00002176. Med Klin (Munich). 2001. PMID: 11253280 German.

6

Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission.

Herrlinger KR, Noftz MK, Dalhoff K, Ludwig D, Stange EF, Fellermann K. Herrlinger KR, et al. Am J Gastroenterol. 2002 Feb;97(2):377-81. doi: 10.1111/j.1572-0241.2002.05473.x. Am J Gastroenterol. 2002. PMID: 11866276

7

[Standard therapy of ulcerative colitis. Evidence- and consensus-based recommendations].

Herrlinger K, Fellermann K, Stange EF. Herrlinger K, et al. Internist (Berl). 2002 Nov;43(11):1367-8, 1371-5. doi: 10.1007/s00108-002-0709-3. Internist (Berl). 2002. PMID: 12524917 Review. German. No abstract available.

8

Crohn's disease: a defensin deficiency syndrome?

Fellermann K, Wehkamp J, Herrlinger KR, Stange EF. Fellermann K, et al. Among authors: herrlinger kr. Eur J Gastroenterol Hepatol. 2003 Jun;15(6):627-34. doi: 10.1097/00042737-200306000-00008. Eur J Gastroenterol Hepatol. 2003. PMID: 12840673 Review.

9

Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis.

Wehkamp J, Harder J, Weichenthal M, Mueller O, Herrlinger KR, Fellermann K, Schroeder JM, Stange EF. Wehkamp J, et al. Among authors: herrlinger kr. Inflamm Bowel Dis. 2003 Jul;9(4):215-23. doi: 10.1097/00054725-200307000-00001. Inflamm Bowel Dis. 2003. PMID: 12902844

10

[The role of defensins in the pathogenesis of chronic-inflammatory bowel disease].

Schmid M, Fellermann K, Wehkamp J, Herrlinger K, Stange EF. Schmid M, et al. Z Gastroenterol. 2004 Apr;42(4):333-8. doi: 10.1055/s-2004-813072. Z Gastroenterol. 2004. PMID: 15095125 Review. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

103 results

Search Page

Filters